Dalton Pharma Services enters agreement with pharmaceutical companyCanada-based Dalton Pharma Services recently entered into an agreement with Clarity Pharmaceuticals, a company based in Sydney, Australia, that focuses on developing radiopharmaceuticals using technology from the Australian Nuclear Science and Technology Organization and the University of Melbourne.

"Our expert capabilities in the manufacture of complex chemical products, including conjugation under sterile cGMP conditions and our strength in aseptic filling, solidified the manufacturing agreement," said Peter Pekos, CEO of Dalton. "We are excited to have the opportunity to work with Clarity in bringing this breakthrough imaging technology from a research setting to the drug development industry. Adding Clarity to our growing list of strategic relationships with innovative clients is an important milestone for Dalton."

The partnership is a strategic move from a supply chain perspective. Dalton will supply Clarity with both manufacturing and analysis services, including chemistry manufacturing and asceptic fill/finish services.

According to Matt Harris, managing director of Clarity, the agreement is part of the company's plan to make its diagnostic tools "quickly available to the pharmaceutical development industry."

Dalton recently received Good Laboratory Practices Certification from The Standards Council of Canada.
Share To:

Strategic Sourceror

Post A Comment:

0 comments so far,add yours